• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 4:22:37 PM ET
    $VIE
    Major Pharmaceuticals
    Health Care
    Get the next $VIE alert in real time by email
    SC 13G/A 1 p21-0635sc13ga.htm VIELA BIO, INC.

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No.  1)*
     

    Viela Bio, Inc.

    (Name of Issuer)
     

    Common Stock, par value of $0.001 per share

    (Title of Class of Securities)
     

    926613100

    (CUSIP Number)
     

    December 31, 2020

    (Date of Event Which Requires Filing of This Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ý Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 7 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     CUSIP No. 92661310013G/APage 2 of 7 Pages

     

    1

    NAME OF REPORTING PERSON

    Hillhouse Capital Advisors, Ltd.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Cayman Islands

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    -0-

    6

    SHARED VOTING POWER

    2,382,414 shares of Common Stock*

    7

    SOLE DISPOSITIVE POWER

    -0-

    8

    SHARED DISPOSITIVE POWER

    2,382,414 shares of Common Stock*

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,382,414 shares of Common Stock*

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    4.3%

    12

    TYPE OF REPORTING PERSON

    IA

             

     

    * Consists of 460,000 shares of Common Stock held by funds managed by Hillhouse Capital Advisors, Ltd. ("HCA") and 1,922,414 shares of Common Stock held by funds managed by Hillhouse Capital Management, Ltd. ("HCM"). HCA and HCM are under common control and share certain policies, personnel and resources.

     

     CUSIP No. 92661310013G/APage 3 of 7 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Hillhouse Capital Management, Ltd.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Cayman Islands

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    -0-

    6

    SHARED VOTING POWER

    2,382,414 shares of Common Stock*

    7

    SOLE DISPOSITIVE POWER

    -0-

    8

    SHARED DISPOSITIVE POWER

    2,382,414 shares of Common Stock*

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,382,414 shares of Common Stock*

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    4.3%

    12

    TYPE OF REPORTING PERSON

    IA

             

     

    * Consists of 460,000 shares of Common Stock held by funds managed by HCA and 1,922,414 shares of Common Stock held by funds managed by HCM. HCA and HCM are under common control and share certain policies, personnel and resources.

     

     CUSIP No. 92661310013G/APage 4 of 7 Pages

     

    Item 1(a). NAME OF ISSUER
      The name of the issuer is Viela Bio, Inc. (the "Company").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES
      The Company's principal executive office is located at One MedImmune Way, First Floor, Area Two, Gaithersburg, MD 20878.

     

    Item 2(a). NAME OF PERSON FILING
     

    This Schedule 13G is filed by: (i) Hillhouse Capital Advisors, Ltd., an exempted Cayman Islands company ("HCA") and (ii) Hillhouse Capital Management, Ltd., an exempted Cayman Islands company ("HCM"). The foregoing persons are hereinafter sometimes each referred to as a "Reporting Person" and collectively referred to as the "Reporting Persons."

     

    HCA acts as the sole management company of Gaoling Fund, L.P. ("Gaoling") and the sole general partner of YHG Investment, L.P. ("YHG"). HCA is hereby deemed to be the beneficial owner of, and to control the voting and investment power of, shares of Common Stock (as defined in Item 2(d) below) held by the Gaoling and YHG. HCM acts as the sole management company of Hillhouse Fund III ("HFIII"). HH RSV-MIM Holdings Limited ("HH RSV-MIM") is wholly owned by HFIII. HCM is hereby deemed to be the beneficial owner of, and to control the voting power of, the Common Stock held by HH RSV-MIM. HCA and HCM are under common control and share certain policies, personnel and resources. Accordingly, each of HCA and HCM reports on this Schedule 13G that it has shared voting and dispositive power of the Common Stock beneficially owned by each of HCA and HCM.

     

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE
      The address of the business office of each of the Reporting Persons is Suite 2202, 22nd Floor, Two International Finance Centre, 8 Finance Street, Central, Hong Kong.

     

    Item 2(c). CITIZENSHIP
      Cayman Islands

     

    Item 2(d). TITLE OF CLASS OF SECURITIES
      Common Stock, par value of $0.001 per share (the "Common Stock").

     

    Item 2(e). CUSIP NUMBER
      926613100

     

     CUSIP No. 92661310013G/APage 5 of 7 Pages

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO Rules 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
      (a) ¨ Broker or dealer registered under Section 15 of the Act;
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act;
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act;
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940;
      (e) ý An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

     

      (g) ¨

    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

     

      (h) ¨

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

      (i) ¨

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).
     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution: __________________

     

    Item 4. OWNERSHIP
      The percentage set forth in this Schedule 13G/A is calculated based upon an aggregate of 54,837,541 shares of Common Stock reported to be issued and outstanding as of November 10, 2020, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2020 filed with the Securities and Exchange Commission on November 10, 2020.
       
      The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: x

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
      See Item 2.

     

     CUSIP No. 92661310013G/APage 6 of 7 Pages

     

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP
      Not applicable.

     

    Item 10. CERTIFICATION  
      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below the Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     CUSIP No. 92661310013G/APage 7 of 7 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE: February 16, 2021

     

    Hillhouse Capital Advisors, LTD.  
       
       
    /s/ Richard A. Hornung  
    Name: Richard A. Hornung  
    Title: General Counsel and Chief Compliance Officer  

     

     

    HILLHOUSE CAPITAL MANAGEMENT, LTD.  
       
       
    /s/ Richard A. Hornung  
    Name: Richard A. Hornung  
    Title: General Counsel and Chief Compliance Officer  

     

     

    Get the next $VIE alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VIE

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VIE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Viela Bio Reports Fourth Quarter and Full Year 2020 Operating and Financial Results

    GAITHERSBURG, Md., March 01, 2021 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for patients suffering from autoimmune and severe inflammatory diseases, today reported financial results and provided program and business highlights for the fourth quarter and full year ended December 31, 2020. “2020 was a year of great progress for Viela, despite the many external challenges resulting from the COVID-19 global pandemic,” said Bing Yao, Ph.D., Chief Executive Officer at Viela Bio. “Most significantly, we received FDA approval for UPLIZNA® to treat adult patients with AQP4+ NMOSD and achieve

    3/1/21 4:01:00 PM ET
    $VIE
    Major Pharmaceuticals
    Health Care

    Viela Bio Announces Additional Positive Results with UPLIZNA® (inebilizumab-cdon) in Patients with Neuromyelitis Optica Spectrum Disorder at the ACTRIMS 2021 Forum

    -No new safety signals were identified with prolonged inebilizumab treatment and inebilizumab-mediated B-cell depletion- -UPLIZNA was shown to be safe and effective in patients with previous exposure to off-label therapy- GAITHERSBURG, Md., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for patients suffering from autoimmune and severe inflammatory diseases, today reported updated safety, efficacy and long-term use results of UPLIZNA® (inebilizumab-cdon), including interim data from the open-label extension period (OLP) of the pivotal N-MOmentum trial in patients with neur

    2/25/21 8:30:00 AM ET
    $VIE
    Major Pharmaceuticals
    Health Care

    Ambrx Appoints Audit Executive Chris Nolet to Board of Directors

    SAN DIEGO--(BUSINESS WIRE)--​Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code to create Engineered Precision Biologics, today announced the appointment of Chris Nolet to the company’s Board of Directors. Mr. Nolet brings extensive experience as a long-time audit partner and business advisor in the life sciences industry, and has assumed the role of Chair of Ambrx’s Audit Committee. “We are delighted that Chris will be joining our Board of Directors given his deep expertise, knowledge base and industry network,” said Feng Tian, Ph.D., President and CEO of Ambrx. “His experience in helping transition clinical stage companies into commercially integra

    2/23/21 4:05:00 PM ET
    $VIE
    $PTE
    $RVNC
    Major Pharmaceuticals
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Biotechnology: Pharmaceutical Preparations

    $VIE
    SEC Filings

    View All

    SEC Form 15-12B filed by Viela Bio, Inc.

    15-12B - Viela Bio, Inc. (0001734517) (Filer)

    3/25/21 4:01:54 PM ET
    $VIE
    Major Pharmaceuticals
    Health Care

    SEC Form S-8 POS filed by Viela Bio, Inc.

    S-8 POS - Viela Bio, Inc. (0001734517) (Filer)

    3/15/21 9:15:53 AM ET
    $VIE
    Major Pharmaceuticals
    Health Care

    SEC Form S-8 POS filed by Viela Bio, Inc.

    S-8 POS - Viela Bio, Inc. (0001734517) (Filer)

    3/15/21 9:12:58 AM ET
    $VIE
    Major Pharmaceuticals
    Health Care

    $VIE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Viela Bio downgraded by Guggenheim

    Guggenheim downgraded Viela Bio from Buy to Neutral

    2/8/21 11:51:17 AM ET
    $VIE
    Major Pharmaceuticals
    Health Care

    Viela Bio downgraded by Wedbush

    Wedbush downgraded Viela Bio from Outperform to Neutral

    2/8/21 7:28:49 AM ET
    $VIE
    Major Pharmaceuticals
    Health Care

    Viela Bio downgraded by Wedbush with a new price target

    Wedbush downgraded Viela Bio from Outperform to Neutral and set a new price target of $43.00

    2/8/21 7:26:43 AM ET
    $VIE
    Major Pharmaceuticals
    Health Care

    $VIE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Yanling Cao disposed to the issuer $441,084,709 worth of Common Stock (8,322,353 units at $53.00)

    4 - Viela Bio, Inc. (0001734517) (Issuer)

    3/16/21 5:13:43 PM ET
    $VIE
    Major Pharmaceuticals
    Health Care

    SEC Form 4 filed by Tyrell Rivers

    4 - Viela Bio, Inc. (0001734517) (Issuer)

    3/16/21 8:53:24 AM ET
    $VIE
    Major Pharmaceuticals
    Health Care

    SEC Form 4 filed by Plc Astrazeneca

    4 - Viela Bio, Inc. (0001734517) (Issuer)

    3/16/21 8:52:55 AM ET
    $VIE
    Major Pharmaceuticals
    Health Care

    $VIE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Viela Bio, Inc.

    SC 13D/A - Viela Bio, Inc. (0001734517) (Subject)

    3/17/21 7:40:24 AM ET
    $VIE
    Major Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - Viela Bio, Inc. (0001734517) (Subject)

    3/10/21 9:46:40 AM ET
    $VIE
    Major Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - Viela Bio, Inc. (0001734517) (Subject)

    2/16/21 4:22:37 PM ET
    $VIE
    Major Pharmaceuticals
    Health Care

    $VIE
    Leadership Updates

    Live Leadership Updates

    View All

    Ambrx Appoints Audit Executive Chris Nolet to Board of Directors

    SAN DIEGO--(BUSINESS WIRE)--​Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code to create Engineered Precision Biologics, today announced the appointment of Chris Nolet to the company’s Board of Directors. Mr. Nolet brings extensive experience as a long-time audit partner and business advisor in the life sciences industry, and has assumed the role of Chair of Ambrx’s Audit Committee. “We are delighted that Chris will be joining our Board of Directors given his deep expertise, knowledge base and industry network,” said Feng Tian, Ph.D., President and CEO of Ambrx. “His experience in helping transition clinical stage companies into commercially integra

    2/23/21 4:05:00 PM ET
    $VIE
    $PTE
    $RVNC
    Major Pharmaceuticals
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Biotechnology: Pharmaceutical Preparations